Archives

Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema

Novo Nordisk NVO announced the submission of a new drug application (NDA) to the FDA, seeking approval for its next-generation once-weekly injection, CagriSema, to reduce excess body weight and maintain weight reduction in the long term in adults with obesity or overweight. The FDA is expected to review the application in 2026. The candidate is intended […]

Did Eli Lilly Just Find the Holy Grail of Weight Loss?

Quick Read Eli Lilly (LLY) submitted an FDA application for orforglipron. The once-daily oral pill maintained weight loss after patients switched from injections. Lilly’s Zepbound achieved 20.2% average weight loss over 72 weeks versus 13.7% for Novo Nordisk‘s Wegovy in a Phase 3 trial. Novo Nordisk’s higher-dose oral semaglutide could be approved by year-end. Lilly’s […]

Lawsuits Allege Ozempic Is Causing Blindness

Ozempic and similar weight loss drugs have been found to cut risks for a variety of health issues — ranging from heart to kidney disease — netting the pharma companies behind them billions of projected dollars in revenue over the next decade. But in rare cases, this class of drugs called GLP-1 agonists can come […]

GLP-1 pills are on the way. Here’s what to know : Short Wave – NPR

GLP-1 pills are on the way. Here’s what to know : Short Wave  NPR Wegovy Maker Novo Nordisk Files for FDA Approval of Obesity Drug CagriSema  The Wall Street Journal Eli Lilly, Novo Nordisk file new weight-loss drugs that could be game changers in obesity medicine  MarketWatch Novo files marketing application for next-gen weight-loss drug  Reuters Healthy Returns: 2026 […]

IJMS, Vol. 27, Pages 27: The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review

IJMS, Vol. 27, Pages 27: The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review International Journal of Molecular Sciences doi: 10.3390/ijms27010027 Authors: Dai Yamanouchi The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) play central roles in metabolic and cardiovascular regulation. GLP-1 receptor agonists (GLP-1RAs) are […]

Maintenance, man: Lilly’s phase III weight trial hits goals

Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase III Attain-Maintain trial with orforglipron, a once-daily oral small molecule GLP-1 receptor agonist. Indianapolis-based Lilly said that at one year orforglipron met the primary and all […]

Employers drop coverage for weight loss drugs as pharma’s direct-to-consumer programs grow – statnews.com

Employers drop coverage for weight loss drugs as pharma’s direct-to-consumer programs grow  statnews.com Opinion | How to cut the velvet rope to GLP-1s  The Washington Post Obesity recognition ‘going in right direction’ amid GLP-1 revolution, but obstacles remain  thehill.com Covering the High Cost of Weight Loss Drugs  National Conference of State Legislatures (NCSL) Study finds 40% of GLP-1 prescriptions […]